The commercialization of Antibody Drug Conjugates (ADCs) has witnessed significant growth and interest in the biopharmaceutical industry. With their potential to offer targeted and potent therapies for various diseases, ADCs have become a focal point for drug development and market expansion.
One key driver of the commercialization of ADCs is the increasing prevalence of cancer and the need for more effective and safer treatments. As a result, several pharmaceutical companies and ... Read more
